Medical Care

Global Pharmaceutical CDMO Market Research Report 2025

The global market for Pharmaceutical CDMO was valued at US$ 148980 million in the year 2024 and is projected to reach a revised size of US$ 248290 million by 2031, growing at a CAGR of 7.7% during the forecast period.
A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.
Contract Pharmaceutical Manufacturing is part of CDMO, refers to accept commissioned from pharmaceutical companies, provide the service about API production, FDF production, packaging.
Pharmaceutical companies are likely to outsource a wide range of manufacturing related activities including – primary and secondary packaging, formulation, active ingredient manufacturing, labeling, clinical supplies, sterilization, manufacturing of chemical intermediates, etc. CDMOs support pharmaceutical companies at all stages of the process of making medicines: by providing services in the research and development stages, by offering support in manufacturing, and by providing formulating and finishing processes.
The key service providers of the Pharmaceutical CDMO in the world are Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, among which the market share of the top three service providers exceeds 10%, and Lonza is the largest service provider. The services provided by global pharmaceutical CDMO are mainly distributed in North America, Europe and China, among which the top three regions account for nearly 60% of the market share, and North America is currently the largest service provider. In terms of its service type, the growth rate of FDF CDMO is relatively fast. At present, the market share of API CDMO is the highest, more than 40%, followed by FDF CDMO, packaging CDMO and clinical CDMO. In terms of its application, pharmaceutical company are the largest application field, with a market share of more than 60%, followed by biotechnology company.
This report aims to provide a comprehensive presentation of the global market for Pharmaceutical CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical CDMO.
The Pharmaceutical CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pharmaceutical CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmaceutical CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
Segment by Type
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO
Segment by Application
Pharmaceutical Company
Biotechnology Company
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmaceutical CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmaceutical CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 API CDMO
1.2.3 FDF CDMO
1.2.4 Packaging CDMO
1.2.5 Clinical CDMO
1.3 Market by Application
1.3.1 Global Pharmaceutical CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceutical CDMO Market Perspective (2020-2031)
2.2 Global Pharmaceutical CDMO Growth Trends by Region
2.2.1 Global Pharmaceutical CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Pharmaceutical CDMO Historic Market Size by Region (2020-2025)
2.2.3 Pharmaceutical CDMO Forecasted Market Size by Region (2026-2031)
2.3 Pharmaceutical CDMO Market Dynamics
2.3.1 Pharmaceutical CDMO Industry Trends
2.3.2 Pharmaceutical CDMO Market Drivers
2.3.3 Pharmaceutical CDMO Market Challenges
2.3.4 Pharmaceutical CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmaceutical CDMO Players by Revenue
3.1.1 Global Top Pharmaceutical CDMO Players by Revenue (2020-2025)
3.1.2 Global Pharmaceutical CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Pharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Pharmaceutical CDMO Revenue
3.4 Global Pharmaceutical CDMO Market Concentration Ratio
3.4.1 Global Pharmaceutical CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical CDMO Revenue in 2024
3.5 Global Key Players of Pharmaceutical CDMO Head office and Area Served
3.6 Global Key Players of Pharmaceutical CDMO, Product and Application
3.7 Global Key Players of Pharmaceutical CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceutical CDMO Breakdown Data by Type
4.1 Global Pharmaceutical CDMO Historic Market Size by Type (2020-2025)
4.2 Global Pharmaceutical CDMO Forecasted Market Size by Type (2026-2031)
5 Pharmaceutical CDMO Breakdown Data by Application
5.1 Global Pharmaceutical CDMO Historic Market Size by Application (2020-2025)
5.2 Global Pharmaceutical CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Pharmaceutical CDMO Market Size (2020-2031)
6.2 North America Pharmaceutical CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Pharmaceutical CDMO Market Size by Country (2020-2025)
6.4 North America Pharmaceutical CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmaceutical CDMO Market Size (2020-2031)
7.2 Europe Pharmaceutical CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Pharmaceutical CDMO Market Size by Country (2020-2025)
7.4 Europe Pharmaceutical CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical CDMO Market Size (2020-2031)
8.2 Asia-Pacific Pharmaceutical CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Pharmaceutical CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Pharmaceutical CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmaceutical CDMO Market Size (2020-2031)
9.2 Latin America Pharmaceutical CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Pharmaceutical CDMO Market Size by Country (2020-2025)
9.4 Latin America Pharmaceutical CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical CDMO Market Size (2020-2031)
10.2 Middle East & Africa Pharmaceutical CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Pharmaceutical CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Pharmaceutical CDMO Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Pharmaceutical CDMO Introduction
11.1.4 Lonza Revenue in Pharmaceutical CDMO Business (2020-2025)
11.1.5 Lonza Recent Development
11.2 Catalent
11.2.1 Catalent Company Details
11.2.2 Catalent Business Overview
11.2.3 Catalent Pharmaceutical CDMO Introduction
11.2.4 Catalent Revenue in Pharmaceutical CDMO Business (2020-2025)
11.2.5 Catalent Recent Development
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Details
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Pharmaceutical CDMO Introduction
11.3.4 Thermo Fisher Scientific Revenue in Pharmaceutical CDMO Business (2020-2025)
11.3.5 Thermo Fisher Scientific Recent Development
11.4 Samsung Biologics
11.4.1 Samsung Biologics Company Details
11.4.2 Samsung Biologics Business Overview
11.4.3 Samsung Biologics Pharmaceutical CDMO Introduction
11.4.4 Samsung Biologics Revenue in Pharmaceutical CDMO Business (2020-2025)
11.4.5 Samsung Biologics Recent Development
11.5 Fareva
11.5.1 Fareva Company Details
11.5.2 Fareva Business Overview
11.5.3 Fareva Pharmaceutical CDMO Introduction
11.5.4 Fareva Revenue in Pharmaceutical CDMO Business (2020-2025)
11.5.5 Fareva Recent Development
11.6 WuXi AppTech
11.6.1 WuXi AppTech Company Details
11.6.2 WuXi AppTech Business Overview
11.6.3 WuXi AppTech Pharmaceutical CDMO Introduction
11.6.4 WuXi AppTech Revenue in Pharmaceutical CDMO Business (2020-2025)
11.6.5 WuXi AppTech Recent Development
11.7 WuXi Biologics
11.7.1 WuXi Biologics Company Details
11.7.2 WuXi Biologics Business Overview
11.7.3 WuXi Biologics Pharmaceutical CDMO Introduction
11.7.4 WuXi Biologics Revenue in Pharmaceutical CDMO Business (2020-2025)
11.7.5 WuXi Biologics Recent Development
11.8 Siegfried
11.8.1 Siegfried Company Details
11.8.2 Siegfried Business Overview
11.8.3 Siegfried Pharmaceutical CDMO Introduction
11.8.4 Siegfried Revenue in Pharmaceutical CDMO Business (2020-2025)
11.8.5 Siegfried Recent Development
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Company Details
11.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Introduction
11.9.4 FUJIFILM Diosynth Biotechnologies Revenue in Pharmaceutical CDMO Business (2020-2025)
11.9.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.10 Asymchem
11.10.1 Asymchem Company Details
11.10.2 Asymchem Business Overview
11.10.3 Asymchem Pharmaceutical CDMO Introduction
11.10.4 Asymchem Revenue in Pharmaceutical CDMO Business (2020-2025)
11.10.5 Asymchem Recent Development
11.11 Pfizer CentreOne
11.11.1 Pfizer CentreOne Company Details
11.11.2 Pfizer CentreOne Business Overview
11.11.3 Pfizer CentreOne Pharmaceutical CDMO Introduction
11.11.4 Pfizer CentreOne Revenue in Pharmaceutical CDMO Business (2020-2025)
11.11.5 Pfizer CentreOne Recent Development
11.12 Delpharm
11.12.1 Delpharm Company Details
11.12.2 Delpharm Business Overview
11.12.3 Delpharm Pharmaceutical CDMO Introduction
11.12.4 Delpharm Revenue in Pharmaceutical CDMO Business (2020-2025)
11.12.5 Delpharm Recent Development
11.13 Recipharm
11.13.1 Recipharm Company Details
11.13.2 Recipharm Business Overview
11.13.3 Recipharm Pharmaceutical CDMO Introduction
11.13.4 Recipharm Revenue in Pharmaceutical CDMO Business (2020-2025)
11.13.5 Recipharm Recent Development
11.14 AGC Pharma Chemicals
11.14.1 AGC Pharma Chemicals Company Details
11.14.2 AGC Pharma Chemicals Business Overview
11.14.3 AGC Pharma Chemicals Pharmaceutical CDMO Introduction
11.14.4 AGC Pharma Chemicals Revenue in Pharmaceutical CDMO Business (2020-2025)
11.14.5 AGC Pharma Chemicals Recent Development
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Company Details
11.15.2 Boehringer Ingelheim Business Overview
11.15.3 Boehringer Ingelheim Pharmaceutical CDMO Introduction
11.15.4 Boehringer Ingelheim Revenue in Pharmaceutical CDMO Business (2020-2025)
11.15.5 Boehringer Ingelheim Recent Development
11.16 Vetter
11.16.1 Vetter Company Details
11.16.2 Vetter Business Overview
11.16.3 Vetter Pharmaceutical CDMO Introduction
11.16.4 Vetter Revenue in Pharmaceutical CDMO Business (2020-2025)
11.16.5 Vetter Recent Development
11.17 Curia
11.17.1 Curia Company Details
11.17.2 Curia Business Overview
11.17.3 Curia Pharmaceutical CDMO Introduction
11.17.4 Curia Revenue in Pharmaceutical CDMO Business (2020-2025)
11.17.5 Curia Recent Development
11.18 Aenova
11.18.1 Aenova Company Details
11.18.2 Aenova Business Overview
11.18.3 Aenova Pharmaceutical CDMO Introduction
11.18.4 Aenova Revenue in Pharmaceutical CDMO Business (2020-2025)
11.18.5 Aenova Recent Development
11.19 Porton
11.19.1 Porton Company Details
11.19.2 Porton Business Overview
11.19.3 Porton Pharmaceutical CDMO Introduction
11.19.4 Porton Revenue in Pharmaceutical CDMO Business (2020-2025)
11.19.5 Porton Recent Development
11.20 Piramal
11.20.1 Piramal Company Details
11.20.2 Piramal Business Overview
11.20.3 Piramal Pharmaceutical CDMO Introduction
11.20.4 Piramal Revenue in Pharmaceutical CDMO Business (2020-2025)
11.20.5 Piramal Recent Development
11.21 Strides Pharma
11.21.1 Strides Pharma Company Details
11.21.2 Strides Pharma Business Overview
11.21.3 Strides Pharma Pharmaceutical CDMO Introduction
11.21.4 Strides Pharma Revenue in Pharmaceutical CDMO Business (2020-2025)
11.21.5 Strides Pharma Recent Development
11.22 NextPharma
11.22.1 NextPharma Company Details
11.22.2 NextPharma Business Overview
11.22.3 NextPharma Pharmaceutical CDMO Introduction
11.22.4 NextPharma Revenue in Pharmaceutical CDMO Business (2020-2025)
11.22.5 NextPharma Recent Development
11.23 Famar
11.23.1 Famar Company Details
11.23.2 Famar Business Overview
11.23.3 Famar Pharmaceutical CDMO Introduction
11.23.4 Famar Revenue in Pharmaceutical CDMO Business (2020-2025)
11.23.5 Famar Recent Development
11.24 Jubilant
11.24.1 Jubilant Company Details
11.24.2 Jubilant Business Overview
11.24.3 Jubilant Pharmaceutical CDMO Introduction
11.24.4 Jubilant Revenue in Pharmaceutical CDMO Business (2020-2025)
11.24.5 Jubilant Recent Development
11.25 Alcami
11.25.1 Alcami Company Details
11.25.2 Alcami Business Overview
11.25.3 Alcami Pharmaceutical CDMO Introduction
11.25.4 Alcami Revenue in Pharmaceutical CDMO Business (2020-2025)
11.25.5 Alcami Recent Development
11.26 Euroapi
11.26.1 Euroapi Company Details
11.26.2 Euroapi Business Overview
11.26.3 Euroapi Pharmaceutical CDMO Introduction
11.26.4 Euroapi Revenue in Pharmaceutical CDMO Business (2020-2025)
11.26.5 Euroapi Recent Development
11.27 Eurofins
11.27.1 Eurofins Company Details
11.27.2 Eurofins Business Overview
11.27.3 Eurofins Pharmaceutical CDMO Introduction
11.27.4 Eurofins Revenue in Pharmaceutical CDMO Business (2020-2025)
11.27.5 Eurofins Recent Development
11.28 Avid Bioservices
11.28.1 Avid Bioservices Company Details
11.28.2 Avid Bioservices Business Overview
11.28.3 Avid Bioservices Pharmaceutical CDMO Introduction
11.28.4 Avid Bioservices Revenue in Pharmaceutical CDMO Business (2020-2025)
11.28.5 Avid Bioservices Recent Development
11.29 BioVectra
11.29.1 BioVectra Company Details
11.29.2 BioVectra Business Overview
11.29.3 BioVectra Pharmaceutical CDMO Introduction
11.29.4 BioVectra Revenue in Pharmaceutical CDMO Business (2020-2025)
11.29.5 BioVectra Recent Development
11.30 CPL
11.30.1 CPL Company Details
11.30.2 CPL Business Overview
11.30.3 CPL Pharmaceutical CDMO Introduction
11.30.4 CPL Revenue in Pharmaceutical CDMO Business (2020-2025)
11.30.5 CPL Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Pharmaceutical CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of API CDMO
Table 3. Key Players of FDF CDMO
Table 4. Key Players of Packaging CDMO
Table 5. Key Players of Clinical CDMO
Table 6. Global Pharmaceutical CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Pharmaceutical CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Pharmaceutical CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Pharmaceutical CDMO Market Share by Region (2020-2025)
Table 10. Global Pharmaceutical CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Pharmaceutical CDMO Market Share by Region (2026-2031)
Table 12. Pharmaceutical CDMO Market Trends
Table 13. Pharmaceutical CDMO Market Drivers
Table 14. Pharmaceutical CDMO Market Challenges
Table 15. Pharmaceutical CDMO Market Restraints
Table 16. Global Pharmaceutical CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Pharmaceutical CDMO Market Share by Players (2020-2025)
Table 18. Global Top Pharmaceutical CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmaceutical CDMO as of 2024)
Table 19. Ranking of Global Top Pharmaceutical CDMO Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Pharmaceutical CDMO Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Pharmaceutical CDMO, Headquarters and Area Served
Table 22. Global Key Players of Pharmaceutical CDMO, Product and Application
Table 23. Global Key Players of Pharmaceutical CDMO, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Pharmaceutical CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Pharmaceutical CDMO Revenue Market Share by Type (2020-2025)
Table 27. Global Pharmaceutical CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Pharmaceutical CDMO Revenue Market Share by Type (2026-2031)
Table 29. Global Pharmaceutical CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Pharmaceutical CDMO Revenue Market Share by Application (2020-2025)
Table 31. Global Pharmaceutical CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Pharmaceutical CDMO Revenue Market Share by Application (2026-2031)
Table 33. North America Pharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Pharmaceutical CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Pharmaceutical CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Pharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Pharmaceutical CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Pharmaceutical CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Pharmaceutical CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Pharmaceutical CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Pharmaceutical CDMO Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Pharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Pharmaceutical CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Pharmaceutical CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Pharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Pharmaceutical CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Pharmaceutical CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 48. Lonza Company Details
Table 49. Lonza Business Overview
Table 50. Lonza Pharmaceutical CDMO Product
Table 51. Lonza Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 52. Lonza Recent Development
Table 53. Catalent Company Details
Table 54. Catalent Business Overview
Table 55. Catalent Pharmaceutical CDMO Product
Table 56. Catalent Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 57. Catalent Recent Development
Table 58. Thermo Fisher Scientific Company Details
Table 59. Thermo Fisher Scientific Business Overview
Table 60. Thermo Fisher Scientific Pharmaceutical CDMO Product
Table 61. Thermo Fisher Scientific Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 62. Thermo Fisher Scientific Recent Development
Table 63. Samsung Biologics Company Details
Table 64. Samsung Biologics Business Overview
Table 65. Samsung Biologics Pharmaceutical CDMO Product
Table 66. Samsung Biologics Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 67. Samsung Biologics Recent Development
Table 68. Fareva Company Details
Table 69. Fareva Business Overview
Table 70. Fareva Pharmaceutical CDMO Product
Table 71. Fareva Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 72. Fareva Recent Development
Table 73. WuXi AppTech Company Details
Table 74. WuXi AppTech Business Overview
Table 75. WuXi AppTech Pharmaceutical CDMO Product
Table 76. WuXi AppTech Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 77. WuXi AppTech Recent Development
Table 78. WuXi Biologics Company Details
Table 79. WuXi Biologics Business Overview
Table 80. WuXi Biologics Pharmaceutical CDMO Product
Table 81. WuXi Biologics Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 82. WuXi Biologics Recent Development
Table 83. Siegfried Company Details
Table 84. Siegfried Business Overview
Table 85. Siegfried Pharmaceutical CDMO Product
Table 86. Siegfried Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 87. Siegfried Recent Development
Table 88. FUJIFILM Diosynth Biotechnologies Company Details
Table 89. FUJIFILM Diosynth Biotechnologies Business Overview
Table 90. FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Product
Table 91. FUJIFILM Diosynth Biotechnologies Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 92. FUJIFILM Diosynth Biotechnologies Recent Development
Table 93. Asymchem Company Details
Table 94. Asymchem Business Overview
Table 95. Asymchem Pharmaceutical CDMO Product
Table 96. Asymchem Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 97. Asymchem Recent Development
Table 98. Pfizer CentreOne Company Details
Table 99. Pfizer CentreOne Business Overview
Table 100. Pfizer CentreOne Pharmaceutical CDMO Product
Table 101. Pfizer CentreOne Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 102. Pfizer CentreOne Recent Development
Table 103. Delpharm Company Details
Table 104. Delpharm Business Overview
Table 105. Delpharm Pharmaceutical CDMO Product
Table 106. Delpharm Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 107. Delpharm Recent Development
Table 108. Recipharm Company Details
Table 109. Recipharm Business Overview
Table 110. Recipharm Pharmaceutical CDMO Product
Table 111. Recipharm Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 112. Recipharm Recent Development
Table 113. AGC Pharma Chemicals Company Details
Table 114. AGC Pharma Chemicals Business Overview
Table 115. AGC Pharma Chemicals Pharmaceutical CDMO Product
Table 116. AGC Pharma Chemicals Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 117. AGC Pharma Chemicals Recent Development
Table 118. Boehringer Ingelheim Company Details
Table 119. Boehringer Ingelheim Business Overview
Table 120. Boehringer Ingelheim Pharmaceutical CDMO Product
Table 121. Boehringer Ingelheim Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 122. Boehringer Ingelheim Recent Development
Table 123. Vetter Company Details
Table 124. Vetter Business Overview
Table 125. Vetter Pharmaceutical CDMO Product
Table 126. Vetter Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 127. Vetter Recent Development
Table 128. Curia Company Details
Table 129. Curia Business Overview
Table 130. Curia Pharmaceutical CDMO Product
Table 131. Curia Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 132. Curia Recent Development
Table 133. Aenova Company Details
Table 134. Aenova Business Overview
Table 135. Aenova Pharmaceutical CDMO Product
Table 136. Aenova Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 137. Aenova Recent Development
Table 138. Porton Company Details
Table 139. Porton Business Overview
Table 140. Porton Pharmaceutical CDMO Product
Table 141. Porton Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 142. Porton Recent Development
Table 143. Piramal Company Details
Table 144. Piramal Business Overview
Table 145. Piramal Pharmaceutical CDMO Product
Table 146. Piramal Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 147. Piramal Recent Development
Table 148. Strides Pharma Company Details
Table 149. Strides Pharma Business Overview
Table 150. Strides Pharma Pharmaceutical CDMO Product
Table 151. Strides Pharma Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 152. Strides Pharma Recent Development
Table 153. NextPharma Company Details
Table 154. NextPharma Business Overview
Table 155. NextPharma Pharmaceutical CDMO Product
Table 156. NextPharma Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 157. NextPharma Recent Development
Table 158. Famar Company Details
Table 159. Famar Business Overview
Table 160. Famar Pharmaceutical CDMO Product
Table 161. Famar Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 162. Famar Recent Development
Table 163. Jubilant Company Details
Table 164. Jubilant Business Overview
Table 165. Jubilant Pharmaceutical CDMO Product
Table 166. Jubilant Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 167. Jubilant Recent Development
Table 168. Alcami Company Details
Table 169. Alcami Business Overview
Table 170. Alcami Pharmaceutical CDMO Product
Table 171. Alcami Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 172. Alcami Recent Development
Table 173. Euroapi Company Details
Table 174. Euroapi Business Overview
Table 175. Euroapi Pharmaceutical CDMO Product
Table 176. Euroapi Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 177. Euroapi Recent Development
Table 178. Eurofins Company Details
Table 179. Eurofins Business Overview
Table 180. Eurofins Pharmaceutical CDMO Product
Table 181. Eurofins Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 182. Eurofins Recent Development
Table 183. Avid Bioservices Company Details
Table 184. Avid Bioservices Business Overview
Table 185. Avid Bioservices Pharmaceutical CDMO Product
Table 186. Avid Bioservices Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 187. Avid Bioservices Recent Development
Table 188. BioVectra Company Details
Table 189. BioVectra Business Overview
Table 190. BioVectra Pharmaceutical CDMO Product
Table 191. BioVectra Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 192. BioVectra Recent Development
Table 193. CPL Company Details
Table 194. CPL Business Overview
Table 195. CPL Pharmaceutical CDMO Product
Table 196. CPL Revenue in Pharmaceutical CDMO Business (2020-2025) & (US$ Million)
Table 197. CPL Recent Development
Table 198. Research Programs/Design for This Report
Table 199. Key Data Information from Secondary Sources
Table 200. Key Data Information from Primary Sources
Table 201. Authors List of This Report


List of Figures
Figure 1. Pharmaceutical CDMO Picture
Figure 2. Global Pharmaceutical CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Pharmaceutical CDMO Market Share by Type: 2024 VS 2031
Figure 4. API CDMO Features
Figure 5. FDF CDMO Features
Figure 6. Packaging CDMO Features
Figure 7. Clinical CDMO Features
Figure 8. Global Pharmaceutical CDMO Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Pharmaceutical CDMO Market Share by Application: 2024 VS 2031
Figure 10. Pharmaceutical Company Case Studies
Figure 11. Biotechnology Company Case Studies
Figure 12. Other Case Studies
Figure 13. Pharmaceutical CDMO Report Years Considered
Figure 14. Global Pharmaceutical CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Pharmaceutical CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Pharmaceutical CDMO Market Share by Region: 2024 VS 2031
Figure 17. Global Pharmaceutical CDMO Market Share by Players in 2024
Figure 18. Global Top Pharmaceutical CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmaceutical CDMO as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Pharmaceutical CDMO Revenue in 2024
Figure 20. North America Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Pharmaceutical CDMO Market Share by Country (2020-2031)
Figure 22. United States Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Pharmaceutical CDMO Market Share by Country (2020-2031)
Figure 26. Germany Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Pharmaceutical CDMO Market Share by Region (2020-2031)
Figure 34. China Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Pharmaceutical CDMO Market Share by Country (2020-2031)
Figure 42. Mexico Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Pharmaceutical CDMO Market Share by Country (2020-2031)
Figure 46. Turkey Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Pharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Lonza Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 50. Catalent Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 51. Thermo Fisher Scientific Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 52. Samsung Biologics Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 53. Fareva Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 54. WuXi AppTech Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 55. WuXi Biologics Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 56. Siegfried Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 57. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 58. Asymchem Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 59. Pfizer CentreOne Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 60. Delpharm Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 61. Recipharm Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 62. AGC Pharma Chemicals Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 63. Boehringer Ingelheim Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 64. Vetter Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 65. Curia Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 66. Aenova Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 67. Porton Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 68. Piramal Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 69. Strides Pharma Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 70. NextPharma Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 71. Famar Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 72. Jubilant Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 73. Alcami Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 74. Euroapi Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 75. Eurofins Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 76. Avid Bioservices Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 77. BioVectra Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 78. CPL Revenue Growth Rate in Pharmaceutical CDMO Business (2020-2025)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies